We showed that two immunizations with the BNT162b2 mRNA vaccine (BioNTech/Pfizer) and/or AZD1222 adenovirus (AstraZeneca) triggered anti-RBD-S1 specific Th1/Tc1 responses in 49%, 34% and 10% of individuals without cancer, with solid tumor and with hematologic cancers, respectively25. This evidence concerns the gene PSMD1 and cancer.